{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113762.1.4.1116.508",
  "meta": {
    "versionId": "12",
    "lastUpdated": "2019-12-04T01:00:20.000-05:00"
  },
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.508",
  "version": "20191204",
  "name": "Flow Cytometry Studies Performed",
  "status": "active",
  "date": "2019-12-04T01:00:20-05:00",
  "publisher": "American Society of Clinical Oncology Steward",
  "compose": {
    "include": [
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "concept": [
          {
            "code": "1012415",
            "display": "Flow cytometry, interpretation"
          },
          {
            "code": "3170F",
            "display": "Flow cytometry studies performed at time of diagnosis or prior to initiating treatment (HEM)"
          },
          {
            "code": "88184",
            "display": "Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker"
          },
          {
            "code": "88185",
            "display": "Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; each additional marker (List separately in addition to code for first marker)"
          },
          {
            "code": "88187",
            "display": "Flow cytometry, interpretation; 2 to 8 markers"
          },
          {
            "code": "88189",
            "display": "Flow cytometry, interpretation; 16 or more markers"
          }
        ]
      }
    ]
  }
}